- Home
- DNMX vs RNA Comparison
DNMX vs RNA Comparison
Compare DNMX & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$8.27
Company Overview
Basic Information| Metric | DNMX | RNA |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 222.5M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DNMX | RNA |
|---|---|---|
| Price | $10.06 | $8.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | 63.4K | ★ 370.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $8.16 |
| 52 Week High | $10.08 | $73.06 |
Technical Indicators
Market Signals| Indicator | DNMX | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 26.00 |
| Support Level | $9.99 | N/A |
| Resistance Level | N/A | $14.39 |
| Average True Range (ATR) | 0.01 | 0.75 |
| MACD | -0.00 | -0.27 |
| Stochastic Oscillator | 25.00 | 3.28 |
Price Performance
Historical Comparison DNMX
RNA
About DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a blank check company.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.